(Q40648657)

22 September 2017

title

Trimodality treatment in Stage III nonsmall cell lung carcinoma: prrognostic impact of K-ras mutations after neoadjuvant therapy (English)

1 reference

22 September 2017

1 reference

3

1 reference

22 September 2017

Petra Broermann

1

1 reference

22 September 2017

Klaus Junker

2

1 reference

22 September 2017

Achim Heinecke

4

1 reference

22 September 2017

Lutz Freitag

5

1 reference

22 September 2017

Folker Klinke

6

1 reference

22 September 2017

Wolfgang E Berdel

7

1 reference

22 September 2017

Michael Thomas

8

1 reference

22 September 2017

language of work or name

English

0 references

publication date

1 April 2002

1 reference

22 September 2017

1 reference

22 September 2017

volume

94

1 reference

22 September 2017

issue

7

1 reference

22 September 2017

page(s)

2055-2062

1 reference

Revisions in the International System for Staging Lung Cancer

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10387

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10387

A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10387

Detection of point mutations in human genes by the solid-phase minisequencing method

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10387

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10387

Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10387

Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10387

K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10387

Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10387

The ras oncogenes increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10387

Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10387

Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10387

Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10387

K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10387

Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10387

Correlation between K-ras gene mutation and prognosis of patients with nonsmall cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10387

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10387

Tumour regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10387

Impact of preoperative bimodality induction including twice-daily radiation on tumor regression and survival in stage III non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10387

Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10387

Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10387

21 January 2018

Identifiers

DOI

10.1002/CNCR.10387

1 reference

22 September 2017

1 reference